Answers are grounded in this paper and cite their sources.
Multi-criteria decision analysis shows efgartigimod is a preferred treatment option in Spain, indicating its value over alternatives.
Efgartigimod has been recognised as a valuable option for gMG AChR+ treatment in Spain by a multidisciplinary panel of experts through the application of MCDA, receiving higher scores compared with ravulizumab, zilucoplan, and rozanolixizumab.
No takes yet. Share an insight, caveat, or question.
Cortés-Vicente et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: